Pure Global AI
NCT06227377Recruiting

QTX3034 in Patients With KRAS G12D Mutation

A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation
Quanta TherapeuticsPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
QTX3034
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Quanta Therapeutics
Location
San Antonio,Salt Lake City,Fairfax, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Feb 05, 2024
End date
Apr 01, 2027
Enrollment
250 participants
Primary outcome

Number of participants with Dose Limiting Toxicities (DLTs),Number of participants with Treatment-emergent Adverse Events (TEAEs)

Summary

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in
 combination with cetuximab.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06227377
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06227377 through Pure Global AI's free database. This Phase 1 trial is sponsored by Quanta Therapeutics and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 250 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.